Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed “DNA surgery”) with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company’s core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston.

Biotechnology

Life Sciences

Therapeutics

GenEditBio Limited

Tian Zhu

This department focuses on research and development in pharmacology and toxicology to enhance product safety and efficacy.

GenEditBio Limited

Org chart

Teams

Pharmacology and Toxicology

Offices

GenEditBio Limited

Org chart

Teams

Pharmacology and Toxicology

Offices

Related companies